Treating Prostate Cancer With Abiraterone and Prednisone

Abiraterone acetate paired with low-dose prednisone is one of the most widely used treatments for advanced prostate cancer, and it works across a broader range of disease stages than many people realize. Originally approved for men whose cancer had progressed after chemotherapy, the combination has since proven effective much earlier in the disease course, including in newly diagnosed metastatic cases and even in high-risk non-metastatic disease. The prednisone component is not there to fight cancer directly; it manages a hormonal side effect of abiraterone that would otherwise cause real problems. Understanding how these two drugs work together, and what to watch for while on them, matters for anyone navigating this treatment.

How Abiraterone Starves the Cancer of Androgens

Prostate cancer cells depend on androgens (male hormones like testosterone) to grow. Standard hormone therapy shuts down the testes, which produce the bulk of those androgens. But the body has backup sources: the adrenal glands and even the tumor cells themselves can manufacture small amounts of androgens from cholesterol. Abiraterone blocks a key enzyme called CYP17 that is essential for this production. By irreversibly inhibiting CYP17, abiraterone cuts off androgen synthesis not just from the testes but from the adrenal glands and the tumor, choking the cancer’s fuel supply at multiple points.¹

This broader blockade is what distinguishes abiraterone from older hormone therapies. Even when the testes have been suppressed with standard androgen deprivation therapy, residual androgen production elsewhere can keep the cancer ticking. Abiraterone was specifically developed to address that remaining hormone activity, and early clinical trials confirmed that its selective, irreversible CYP17 inhibition was both safe and capable of producing durable responses in men whose cancer had already become resistant to conventional hormone suppression.²

Why Prednisone Is Part of the Regimen

When you block CYP17, you do not only shut down androgen production. You also reduce the production of cortisol, one of the body’s essential stress hormones. The brain detects falling cortisol levels and responds by ramping up a signaling hormone called ACTH, which tells the adrenal glands to work harder. Because the CYP17 pathway is blocked, the adrenals cannot make more cortisol, but they can funnel their activity into making mineralocorticoids instead. The result is an excess of mineralocorticoids, which drives fluid retention, high blood pressure, and dangerously low potassium levels.

Prednisone at a dose of 5 mg twice daily acts as a cortisol replacement. By providing the cortisol the body needs, it prevents that compensatory surge in ACTH and keeps mineralocorticoid production under control.³ Think of prednisone here not as a cancer drug or even an anti-inflammatory, but as a thermostat that keeps the adrenal system from overcompensating when abiraterone disrupts its normal pathway.

Even with prednisone on board, mineralocorticoid excess is not always fully prevented. Early trials of abiraterone without any steroid showed that a majority of patients developed symptoms of mineralocorticoid excess, and adding the standard 10 mg daily dose of prednisone still left some patients with breakthrough hypertension or low potassium.⁴ That is why regular blood pressure monitoring and potassium checks remain essential throughout treatment.⁵

The Prednisone Dose Question

The approved regimen calls for 5 mg of prednisone twice a day (10 mg total). But in practice, some clinicians have tried reducing the dose to 5 mg once daily, partly out of concern about long-term steroid side effects. A study examining this directly found that patients on the full twice-daily schedule had roughly half the rate of new hypertension and low potassium events compared with those on 5 mg once daily over 24 weeks. The difference was substantial and held up whether measured by diagnosis codes or by actual blood pressure readings and lab values.⁶ For patients with existing high blood pressure or cardiovascular risk factors, skimping on the prednisone dose can create problems that outweigh the steroid risks it was meant to avoid.

That said, the steroid-related side effects from this low dose of prednisone are relatively modest. In a large analysis from clinical trials, roughly a quarter of patients experienced any steroid-associated side effect at any grade, with hyperglycemia (around 7-8%) and weight gain (around 4%) being the most common. Severe steroid-related events occurred in only about 5% of patients, and importantly, these rates did not increase with longer treatment duration, even beyond 30 months of use.⁷

What the Trials Show in Castration-Resistant Disease

Abiraterone with prednisone was first proven in men whose castration-resistant prostate cancer (CRPC) had already progressed after docetaxel chemotherapy. In the pivotal phase 3 trial, men who received abiraterone plus prednisone lived a median of about 16 months compared with roughly 11 months for prednisone alone, a meaningful difference in a population with few remaining options. Response rates, time to disease progression on imaging, and time to rising PSA levels all favored the abiraterone group.⁸

Beyond survival numbers, quality of life matters enormously in advanced cancer. Among men with castration-resistant disease who had not yet received chemotherapy, abiraterone plus prednisone delayed the progression of pain by roughly eight months compared with prednisone alone, and it took significantly longer for daily functioning and overall quality of life to deteriorate.⁹ Prostate cancer that has spread to bone can cause severe pain, so treatments that slow pain progression while extending life carry weight that raw survival statistics do not fully capture.

Moving Abiraterone Earlier in Newly Diagnosed Disease

The bigger shift in how abiraterone is used came when trials showed it was even more effective when started earlier, in men with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) who were beginning standard hormone therapy for the first time. In the LATITUDE trial, adding abiraterone plus prednisone to standard androgen deprivation therapy produced a median radiographic progression-free survival of 33 months versus about 15 months for hormone therapy alone. At the planned interim analysis, median overall survival had not yet been reached in the abiraterone group, while the control group’s median was roughly 35 months.¹⁰

A meta-analysis pooling data from major trials in this setting confirmed the picture: adding abiraterone to standard hormone therapy reduced the risk of death by about 38% and the risk of disease progression by about 55%, translating to an absolute improvement in three-year survival of roughly 14 percentage points.¹¹ Patient-reported outcomes from the LATITUDE trial mirrored this: the time to worsening pain, fatigue, and functional decline was meaningfully delayed when abiraterone was on board from the start.¹²

High-Risk Non-Metastatic Prostate Cancer

Perhaps the most surprising expansion of abiraterone’s role has been into high-risk prostate cancer that has not yet spread to distant sites. The STAMPEDE platform trial tested abiraterone plus a steroid (prednisolone, the British equivalent of prednisone) in men with high-risk non-metastatic disease. With a median follow-up of six years, six-year metastasis-free survival was 82% in the combination group versus 69% in the control group, a reduction in the risk of metastasis or death of nearly half.¹³ The researchers concluded that abiraterone with prednisolone should be considered a new standard treatment for this population.

A broader meta-analysis that pooled data from six trials in high-risk patients confirmed significant improvements in overall survival, progression-free survival, and the time before PSA levels began rising.¹⁴ The trend in recent years has been clear: the earlier abiraterone is introduced in the disease trajectory, the larger its benefit appears to be.

Cardiovascular and Metabolic Risks to Watch

The survival benefits are real, but abiraterone carries cardiovascular and metabolic risks that deserve honest discussion. A meta-analysis of trials involving abiraterone and similar agents found that abiraterone significantly increased the risk of both cardiac events and hypertension compared with controls, at all severity grades.¹⁵ A large study tracking real-world outcomes in men with advanced prostate cancer reported that abiraterone users had roughly 1.8 times the risk of a major cardiovascular event and about 1.8 times the risk of a diabetic event compared with men not on the drug.¹⁶

Post-marketing data paint a similar picture: over a quarter of patients experienced the development or worsening of cardiovascular and metabolic conditions, though few had to stop abiraterone because of these side effects.¹⁷ For men with pre-existing heart disease, diabetes, or significant cardiovascular risk factors, this means coordinating closely with a cardiologist or primary care physician throughout treatment. The oncologist manages the cancer; someone else needs to keep an eye on the heart and blood sugar.

When Abiraterone Stops Working

Nearly all patients eventually develop resistance to abiraterone. One well-studied mechanism involves a variant of the androgen receptor called AR-V7, which the cancer cell produces in a truncated form that no longer needs androgens to activate. When AR-V7 is detectable in a patient’s blood, the response to abiraterone is dismal. In one study, patients who tested positive for AR-V7 had a zero percent PSA response rate to abiraterone, compared with 68% in AR-V7-negative patients. Their median overall survival was roughly 11 months versus a median that had not yet been reached in the AR-V7-negative group.¹⁸ A meta-analysis confirmed that AR-V7-positive patients treated with abiraterone had roughly six to seven times worse progression-free survival than those who tested negative.¹⁹

Detecting AR-V7 through a blood test (liquid biopsy) is becoming an increasingly practical tool for guiding treatment decisions. In a validation study, patients with a positive AR-V7 test had a median overall survival of only about 5.5 months on abiraterone, compared with over 22 months for AR-V7-negative patients.²⁰ For these patients, switching to chemotherapy or other treatment approaches is likely a better path than continuing hormone-based therapy.

Drug Sequencing With Enzalutamide

Abiraterone and enzalutamide both target the androgen pathway but in different ways, and the order in which they are used matters. A crossover trial that randomized patients to receive either abiraterone first followed by enzalutamide, or the reverse, found a clear winner: abiraterone first, then enzalutamide. Enzalutamide retained meaningful activity as a second-line agent, with a 36% PSA response rate, while abiraterone used second after enzalutamide produced a response rate of only 4%.²¹ This makes intuitive sense: enzalutamide blocks the androgen receptor itself, so it can still work even after abiraterone’s upstream blockade of androgen production has been exhausted. But going the other direction, by the time enzalutamide has failed, the cancer has typically found ways around the androgen receptor pathway that make abiraterone less effective.

Real-world data comparing the two drugs head-to-head in first-line use for castration-resistant disease suggest modestly longer survival with enzalutamide, with an adjusted median overall survival of about 22.5 months compared with roughly 20.5 months for abiraterone.²² The difference is real but not enormous, and the choice between them in practice often comes down to side-effect profiles, patient preferences, and whether the steroid component of abiraterone is welcome or undesirable for a given patient.

Combining Abiraterone With PARP Inhibitors

Some of the most promising recent developments involve pairing abiraterone with PARP inhibitors, drugs originally developed for cancers with DNA repair defects. A major trial showed that adding olaparib to abiraterone extended imaging-based progression-free survival from about 16.6 months to roughly 24.8 months in men with castration-resistant disease, regardless of whether they carried mutations in DNA repair genes like BRCA.²³ The most common added side effects were anemia, fatigue, and nausea, consistent with what is expected from PARP inhibitors.

Laboratory research has further suggested that maintaining abiraterone alongside a PARP inhibitor even after abiraterone resistance develops may provide better tumor control than using the PARP inhibitor alone, particularly in cancers carrying BRCA or other DNA repair mutations.²⁴ This combination strategy is still evolving, but it has already changed practice for a subset of patients.

The Steroid Switch Trick

When PSA levels start rising on abiraterone plus prednisone but the patient has not developed clear symptomatic or radiographic progression, some oncologists try swapping prednisone for dexamethasone, a more potent steroid, rather than immediately abandoning abiraterone altogether. Studies of this approach have shown that roughly 30-56% of patients experience a PSA decline or stabilization after the switch, with one study reporting a median progression-free survival on the new steroid combination of about 10 months and a combined time on all abiraterone-based therapy of around 20 months.²⁵ Another study found that the best PSA decline of at least 30% was achieved in about 46% of patients after switching to dexamethasone.²⁶ This is not a guaranteed second wind, but it is a low-risk, low-cost maneuver that can extend the useful life of abiraterone for selected patients before moving on to chemotherapy or another agent.

Taking Abiraterone With Food to Cut Costs

The approved dosing for abiraterone is 1,000 mg taken on an empty stomach. But abiraterone’s absorption increases dramatically when taken with food, and this matters for cost. Studies have shown that 250 mg taken with a low-fat meal produces similar drug levels to the full 1,000 mg fasting dose, at roughly 75% lower cost.²⁷ This is not just a research curiosity. In many parts of the world, abiraterone’s price puts it out of reach: in one survey of Nigerian health professionals, two-thirds reported that fewer than 20% of their patients could afford abiraterone at standard dosing, and nearly 90% believed a low-dose option would improve compliance.²⁸

In high-income countries, cost-effectiveness analyses generally show that abiraterone plus standard hormone therapy is a reasonable value in newly diagnosed metastatic disease. One US-based analysis estimated the cost at roughly $21,000 per quality-adjusted life-year gained, well below the commonly used threshold of $100,000.²⁹ But in low- and middle-income countries, where generic versions may not yet be available or priced affordably, the low-dose-with-food strategy could be transformative.

Adding a Second Androgen Receptor Agent

A separate question from sequencing drugs one after another is whether stacking two androgen-targeting agents at the same time offers additional benefit. The ACIS trial tested adding apalutamide (another androgen receptor blocker) on top of abiraterone plus prednisone in men with castration-resistant disease. Radiographic progression-free survival improved from about 16.6 months with abiraterone plus prednisone alone to roughly 24 months with the triplet, and this benefit held up with longer follow-up.³⁰ Whether this additional delay in progression translates into longer overall survival remains less certain, and the added side effects of a second agent need to be weighed carefully. But the result underscores that the androgen pathway can sometimes be squeezed harder with combination approaches.